In 2019, CartiLife was granted sale authorization as an autologous chondrocyte derived cartilaginous cell therapy for structural restoration of cartilage defect and symptom alleviation
Our tissue model has been registered as an international standard model in the OECD guidelines in 2019. Our human tissue models are sold for the purpose of assessing the toxicity and effectiveness of chemicals, cosmetics, household goods and medicines on the human body, and also used to provide research service by the company
The company has obtained sale authorization of KeraHeal as a cell-based therapy product in 2006 and was registered as part of the industrial insurance benefits in 2009. In October 2015, we obtained sale authorization and industrial insurance benefit registration for Keraheal-Allo which is a thermosensitive hydrogel-type allogeneic keratinocyte therapy product
Human stem cell growth media Stem-Soo and the peptide component BSP-11 are sold as cosmetic ingredients which are capable of improving wrinkles, skin whitening and elasticity restoration
俄罗斯骨关节炎患者术后采访视频
CartiLife 宣传视频
李定宣CTO采访视频